Next-generation sequencing (NGS) is increasingly built into oncology trials as more therapies hinge on biomarker tests. Thermo Fisher Scientific reports 24-hour specimen-to-report turnaround on its Ion Torrent Genexus System versus multi-week central-lab workflows. Faster readouts can help reduce screen failures when sites are searching for rare mutations and have limited tissue, a challenge when screen…